You are here: Industry Insights > Stelara

News List

J&J's 2Q Pharma Sales Up 17% contractpharma
July 30, 2021
STELARA and DARZALEX sales drive growth with sales up 34% to $2.3 billion and up 59% to $1.4 billion in the quarter, respectively.
Johnson & Johnson reports 27.1% increase in Q2 2021 sales pharmaceutical-technology
July 23, 2021
Johnson & Johnson (J&J) has reported sales of $23.31bn in the second quarter (Q2) of 2021, an increase of 27.1% compared to $18.33bn in the same quarter last year.
Stelara® “a compelling option” for the treatment of Crohn’s disease europeanpharmaceuticalreview
May 25, 2021
Janssen has released abstracts for four studies evaluating Stelara® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC).
Johnson & Johnson 1Q Results contractpharma
April 21, 2021
Pharmaceutical sales up 10% in the quarter driven by DARZALEX, STELARA, INVEGA SUSTENNA, and IMBRUVICA.
Janssen presents five year data of STELARA in treatment of Crohn’s Disease expresspharma
October 14, 2020
Over half of the patients with moderately to severely active CD who were randomised to subcutaneous ustekinumab every eight weeks and continued to receive this dosage in the LTE study maintained clinical response and remission through five years of ...
FDA Approves STELARA for Pediatric Patients with Moderate to Severe Plaque Psoriasis americanpharmaceuticalreview
August 11, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for STELARA® (ustekinumab) as a treatment for pediatric patients (6-11 years of age) with the skin les
US expands scope of Janssen's Stelara pharmatimes
August 04, 2020
Janssen's Stelara (ustekinumab) has been approved in the US as a treatment for paediatric patients (six-11 years of age) who struggle with the skin lesions or plaques associated with moderate to severe plaque psoriasis.
Final NICE green light for Janssen's Stelara in UC pharmatimes
June 18, 2020
The National Institute for Health and Care Excellence (NICE) has now issued a final green light for NHS use of Janssen's Stelara (ustekinumab) to treat ulcerative colitis.
SMC accepts Janssen’s ulcerative colitis drug Stelara for NHS use pharmaceutical-technology
April 17, 2020
Scottish Medicines Consortium (SMC) has accepted Janssen Pharmaceutical’s Stelara (ustekinumab) for use on the National Health Service (NHS) Scotland to treat moderately to severely active ulcerative colitis (UC) in adults.
EC expands label of Janssen’s Stelara to include ulcerative colitis pharmaceutical-technology
September 10, 2019
Johnson & Johnson subsidiary Janssen has announced the European Commission (EC) has approved Stelara (ustekinumab) for patients with moderately to severely active ulcerative colitis (UC).

Previous page 1 2 Next page